Articles tagged with Chemotherapy
Recent studies suggest that preoperative chemotherapy can be effective in early breast cancer treatment, but individual responses may vary. Additionally, a case-control study found no increased risk of cancer among frequent blood donors. Furthermore, researchers have identified a novel mechanism to overcome resistance to targeted thera...
A randomized controlled trial found that high-dose chemotherapy did not increase survival rates for patients with small cell lung cancer. Despite increased tumor shrinkage, the high-intensity approach was deemed ineffective and highly toxic.
Researchers used nanotechnology to target tumors in rabbits, achieving a 1,000-fold reduction in chemotherapy dose while slowing tumor growth. The nanoparticles delivered a fungal toxin called fumagillin directly to growing blood vessels, inhibiting tumor expansion.
A study integrating genetic information with breast cancer risk factors refines estimates of relapse-free survival and predicts response to chemotherapy. Gene expression signatures provide valuable insights into breast cancer heterogeneity, enabling more precise clinical outcomes.
Researchers have created a novel nanomachine, called nanoimpeller, that can capture and store anticancer drugs inside tiny pores and release them into cancer cells in response to light. The device has strong implications for cancer treatment and may open a new avenue for drug delivery under external control.
Researchers at USC have found that fasting for two days protects healthy cells from chemotherapy, while leaving cancer cells vulnerable. This discovery holds promise for developing more selective and less toxic chemotherapy treatments.
The EORTC Intergroup trial found that chemotherapy plus surgery on liver tumors improved progression-free survival by 26% in patients with colorectal cancer. Patients who received chemotherapy before and after surgery had a higher rate of progression-free survival compared to those who underwent surgery alone.
Researchers at IUPUI have created the first 3-D image of how bleomycin targets and binds to DNA. This breakthrough study may lead to improved chemotherapy drugs for various cancers.
AstraZeneca's investigational cancer drug vandetanib has completed patient enrollment in two pivotal Phase III studies for the second-line treatment of non-small cell lung cancer. The ZODIAC and ZEAL studies aim to assess the efficacy of vandetanib in combination with chemotherapy treatments.
A study of 61 patients with follicular non-Hodgkin lymphoma found that radioimmunotherapy with yttrium-90 ibritumombab tiuxetan was well-tolerated and effective, achieving complete response in 55 patients. The treatment also showed improved progression-free survival and overall survival rates.
A randomized clinical trial found that postoperative chemotherapy does not improve survival in patients with localized gastric cancer. Despite promising results in advanced gastric cancer, the combination of cisplatin, epirubicin, and other chemotherapies did not show significant benefits.
A new study has demonstrated a lower risk of cardiac toxicity with dose-dense chemotherapy in early-stage HER2-positive breast cancer patients. The regimen, which administers standard doses of chemotherapy agents more frequently, pairs safely with trastuzumab and resulted in only 1.4% cardiac events after 28 months of follow-up.
A study found that adding gemcitabine to chemoradiation improved survival rates for pancreatic cancer patients who had surgery, but the benefit was not statistically significant. The treatment reduced local relapse and systemic metastasis in patients.
Differences in gene expression levels between people of European and African ancestry can impact how they respond to certain drugs. The study found significant differences in several unrelated processes, including genes involved in producing antibodies to microbial invaders.
Research finds that TS genotype is associated with protein expression levels, which can predict patient response to 5-FU-based chemotherapy. Patients with triple-repeated genotypes have higher intratumoral TS protein expression and better clinical outcomes.
A study found that people with gliomatosis cerebri missing chromosome 1p and 19q respond better to temozolomide and live longer. The genetic signature was associated with a higher response rate and longer survival, making temozolomide a preferred treatment option.
A new study reveals that Avastin's side effects may be caused by the blockage of VEGF, which normally protects brain cells from fluid leakage. In mice, this blockage led to brain swelling and cell death.
A team of researchers has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with cisplatin and carboplatin. They found that secondary mutations on the BRCA2 gene restore DNA repair function, making cancer cells resistant to chemotherapy.
Researchers identify nerve that transmits signals of chemotherapy-associated illness from small intestine to brain, offering new approach to reduce debilitating side effects. Anorexia and cachexia often accompany chemotherapy symptoms, compromising patient's nutritional status.
Research reveals high-dose methotrexate significantly increases average survival rate to 4.5 years, outperforming radiation therapy with a one-year average survival rate.
A study of 227 breast cancer patients found that those who participated in a psychological intervention program had better health and functioning scores, with a 7% increase compared to non-participants. The program included training on relaxation, coping with stress, and strategies for improving health behaviors, resulting in fewer sym...
Researchers at Northwestern University successfully synthesized a new natural compound that exhibits promising anti-cancer properties, outperforming existing treatments. By identifying the correct molecular structure, the team is now poised to develop more effective and selective cancer therapies.
Researchers create a localized and controlled drug delivery system that is invisible to the immune system, providing a potential solution for cancer and other diseases. The system uses nanoscale polymer films to slowly release anti-inflammatory drugs, reducing side effects and enhancing treatment efficacy.
A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.
Researchers at the University of East Anglia have discovered a genetic pathway that makes cancerous leukaemia cells resistant to treatment. Inhibiting this pathway, called hemeoxygenase-1 (HO-1), reverts the cells to respond to death-inducing agents.
A randomized clinical trial found that adding docetaxel to anthracycline-based chemotherapy improved disease-free survival in breast cancer patients. The study showed a 4% increase in five-year disease-free survival rates, with patients receiving sequential docetaxel after doxorubicin having the best outcomes.
Research from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) found that chemotherapy safely reduced recurrence, breast cancer mortality, and death from any cause in women with hormone-resistant breast cancer. The study showed a 10-year risk reduction of 25% in younger women and 39% in women aged 50-69 years.
A large clinical trial found that bevacizumab significantly prolongs progression-free survival for women with recurrent breast cancer when combined with chemotherapy. The study showed a doubling of delay in worsening of the disease and improved remission rates compared to chemotherapy alone.
The study found that anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens for women with HER2-positive tumors. However, the treatment showed no significant benefit for patients with HER2-negative breast cancer.
Researchers at Berkeley Lab have produced the first 3D structural images of a DNA-bound Type II topoisomerase, a prime target for antibacterial and anticancer drugs. The study reveals that topo II employs a 'two-gate' mechanism to carry out its tasks, controlling the passage of DNA segments through the enzyme.
Researchers found that erythropoietin administration can prevent acute cardiotoxic effects induced by chemotherapy agents doxorubicin and trastuzumab. The study suggests that rhEPO may be used to reduce acute cardiotoxic effects during chemotherapy, potentially preventing long-term development of cardiomyopathy.
The QUASAR trial found that chemotherapy with fluorouracil and folinic acid reduces the risk of recurrence by 22% and death by 18% in patients with stage II colorectal cancer. The absolute improvements are small, but still significant.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
A Phase III clinical trial shows that patients with relapsed CLL who achieve complete response with oblimersen combination therapy live significantly longer than those treated with chemotherapy alone. The median survival time for oblimersen-treated patients is estimated to exceed 49 months, whereas it was 35 months for those on F/C alone.
Researchers found that nonmyeloablative stem-cell transplant patients have similar outcomes regardless of whether they receive related or unrelated donor cells, with no significant differences in mortality rates. The study suggests that the combination of immunosuppressive drugs and mini-transplant biology may be responsible for the co...
Scientists have developed a retinal flow cytometer that allows for continuous monitoring of circulating cells in a mouse's bloodstream. This technology holds promise for treating multiple myeloma by enabling the testing of chemotherapy agents and treatment strategies.
Bioengineers at Yale have created a new method of drug delivery that effectively targets and treats brain tumors by adding a water-soluble polymer to the anti-cancer drug. This approach has the potential to increase treatment distances, potentially preventing recurrence and improving treatment outcomes.
A new method of administering antiemetic granisetron, subcutaneously, achieves similar blood concentrations as intravenous administration, making it a potential alternative for non-hospitalized patients. The study supports the use of subcutaneous granisetron for treating chemotherapy-induced vomiting.
Researchers found that gene signatures can predict which chemotherapy regimens are most effective for breast cancer patients. The study showed a significant improvement in response rates when using gene signatures to select treatments, suggesting a potential breakthrough in personalized medicine.
Researchers found that simultaneous treatment resulted in a five-year survival rate of 15.1 percent, compared to 10.6 percent with sequential therapy. The study's findings suggest that concurrent chemotherapy and radiation is the new standard of care for locally advanced non-small cell lung cancer.
Rice scientists have successfully grown hairy roots for 4-and-a-half years, a breakthrough that could lead to mass production of medicines like vincristine and vinblastine. The transgenic roots contain genes from both the host plant and bacteria, offering a stable alternative to traditional cell cultures.
Researchers found that quantitative index adds accurate information about patients' responses to first-line chemotherapy, improving tumor response prediction. This method can also identify disease transformation and shorten treatment for favorable responders.
A new study found that a combination of bevacizumab (Avastin) and chemotherapy may increase survival time for patients with glioblastoma multiforme, a deadly type of brain tumor. The treatment showed promising results in improving outcomes for patients who have already been diagnosed with the disease.
Researchers examined the effectiveness of intra-arterial combination chemotherapy in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The treatment led to a median survival time of 457.2 days and a one-year survival rate of 70%.
Researchers have developed nanodiamond clusters that efficiently carry and release chemotherapy drugs, sparing healthy cells from toxicity. The material's stability, safety, and high surface area make it a promising alternative to current drug delivery agents.
A recent study found that women with HER-2 positive breast cancer who receive Taxol alongside chemotherapy experience improved survival rates. In contrast, estrogen-receptor-positive and HER-2-negative patients do not benefit from the added treatment, offering a targeted approach to personalized medicine.
Research suggests that young women with estrogen receptor-positive (ER+) breast cancer who undergo adjuvant chemotherapy do not experience higher survival rates than those with ER-negative tumors. The study, published in Breast Cancer Research, found a 5% difference in survival rates between the two groups.
A new study found that cancer patients receiving chemotherapy did not notice restrictions in their treatment access following the enactment of the Medicare Prescription Drug, Improvement and Modernization Act. Despite significant reductions in government reimbursement to oncologists, patients perceived no barriers to their care.
A study of 447 patients with multiple myeloma found that thalidomide improved overall survival and response rates compared to standard chemotherapy. The MPT regimen was associated with significantly better outcomes, making it a potential new treatment option for elderly patients.
A new study found that gemcitabine chemotherapy after surgery doubles disease-free survival from 4.9 to 11.4 months in patients with operable pancreatic cancer, improving outcomes by 41 percent
Pertuzumab prolongs survival time for women with Stage 3 ovarian cancer, a Phase II clinical trial found. The experimental drug added weeks to the standard survival period and was well-tolerated by the body.
A study suggests that patients with non-squamous histology achieve statistically significant higher survival when treated with ALIMTA in the second-line setting compared to those with squamous histology. The analysis also identified other predictive factors for potential benefit from treatment, including adenocarcinoma histology and go...
A large study of European patients has identified promising biomarkers to distinguish between patients with a high likelihood and low likelihood of relapse, paving the way for more targeted treatment approaches.
The experimental drug STA-4783 has been shown to delay cancer progression and prolong patient lives by inducing oxidative stress in cancer cells. In a randomized trial, patients treated with the combination of STA-4783 and chemotherapy lived up to 12 months after diagnosis, compared to 7.8 months for those receiving only chemotherapy.
A new method of molecular profiling has accurately predicted which stage II colon cancer patients are most likely to have their disease recur after surgery. The analysis identified two groups with distinct clinical outcomes, allowing for more accurate selection of patients who would benefit from adjuvant chemotherapy.
Researchers found that high BRCA1 expression in non-small cell lung cancer patients is associated with poor survival and increased risk of death. Patients with high BRCA1 levels may benefit from taxane-based chemotherapy, while those with low levels may not respond to cisplatin-based treatments.
Research shows PET scans with fluorodeoxyglucose (FDG) can predict a breast tumor's response to chemotherapy and a patient's likelihood of survival. Women with high initial FDG uptake and significant reduction after treatment are more likely to achieve complete response.
Scientists have developed a method to detect circulating tumour cells (CTCs) in blood before and after chemotherapy treatment, potentially identifying patients at risk of cancer recurrence. The study found that CTCs persisted in the blood of patients who were more likely to experience recurrence.
A two-year study from the University of Pittsburgh School of Medicine found that women who took a weekly dose of risedronate lost significantly less bone than those who did not take the drug. Risedronate improved bone density and prevented excess bone loss in breast cancer survivors, even among those on aromatase inhibitors.